PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis of advanced tumors, but excessive immune responses can also induce immune-related adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ke, Kong, Xiangyi, Li, Yuan, Wang, Zhongzhao, Zhang, Lin, Xuan, Lixue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971753/
https://www.ncbi.nlm.nih.gov/pubmed/35370736
http://dx.doi.org/10.3389/fphar.2022.854967
_version_ 1784679701608923136
author Zhang, Ke
Kong, Xiangyi
Li, Yuan
Wang, Zhongzhao
Zhang, Lin
Xuan, Lixue
author_facet Zhang, Ke
Kong, Xiangyi
Li, Yuan
Wang, Zhongzhao
Zhang, Lin
Xuan, Lixue
author_sort Zhang, Ke
collection PubMed
description Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis of advanced tumors, but excessive immune responses can also induce immune-related adverse events (irAEs). Due to this concern, many clinical trials exclude cancer patients with preexisting autoimmune disease (AID). This review outlines the possible mechanisms of irAE, discusses the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients with preexisting AID, and emphasizes the importance of early recognition, continuous monitoring, and multidisciplinary cooperation in the prevention and management of cancer patients with preexisting AID.
format Online
Article
Text
id pubmed-8971753
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89717532022-04-02 PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases Zhang, Ke Kong, Xiangyi Li, Yuan Wang, Zhongzhao Zhang, Lin Xuan, Lixue Front Pharmacol Pharmacology Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis of advanced tumors, but excessive immune responses can also induce immune-related adverse events (irAEs). Due to this concern, many clinical trials exclude cancer patients with preexisting autoimmune disease (AID). This review outlines the possible mechanisms of irAE, discusses the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients with preexisting AID, and emphasizes the importance of early recognition, continuous monitoring, and multidisciplinary cooperation in the prevention and management of cancer patients with preexisting AID. Frontiers Media S.A. 2022-03-18 /pmc/articles/PMC8971753/ /pubmed/35370736 http://dx.doi.org/10.3389/fphar.2022.854967 Text en Copyright © 2022 Zhang, Kong, Li, Wang, Zhang and Xuan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Ke
Kong, Xiangyi
Li, Yuan
Wang, Zhongzhao
Zhang, Lin
Xuan, Lixue
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
title PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
title_full PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
title_fullStr PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
title_full_unstemmed PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
title_short PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
title_sort pd-1/pd-l1 inhibitors in patients with preexisting autoimmune diseases
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971753/
https://www.ncbi.nlm.nih.gov/pubmed/35370736
http://dx.doi.org/10.3389/fphar.2022.854967
work_keys_str_mv AT zhangke pd1pdl1inhibitorsinpatientswithpreexistingautoimmunediseases
AT kongxiangyi pd1pdl1inhibitorsinpatientswithpreexistingautoimmunediseases
AT liyuan pd1pdl1inhibitorsinpatientswithpreexistingautoimmunediseases
AT wangzhongzhao pd1pdl1inhibitorsinpatientswithpreexistingautoimmunediseases
AT zhanglin pd1pdl1inhibitorsinpatientswithpreexistingautoimmunediseases
AT xuanlixue pd1pdl1inhibitorsinpatientswithpreexistingautoimmunediseases

Ejemplares similares